Quantum Computing Stocks Are Falling. Should You Buy IonQ or D-Wave, or Just Stick With Nvidia?

IonQ shares are down 37% over the past month and D-Wave Quantum down 28%, as both quantum pure plays remain high-risk and dependent on government-linked funding (IonQ: $100M+ Air Force Research Lab contracts; D-Wave: $100M Chips Act letter of intent). IonQ reported Q1 2026 revenue of $64.7M (+755% YoY) and raised full-year guidance to $260M–$270M, while D-Wave’s Q1 revenue fell to $2.9M (-81% YoY) though Q1 bookings rose to $33.4M. The article argues Nvidia is the lower-risk way to play quantum-related demand via NVQLink and CUDA-Q (launched Oct 2025), noting Nvidia’s fiscal Q1 2027 revenue was $81.6B with $75.2B from data center, so near-term quantum upside is characterized as “optionality.”

Analysis

The market is likely mispricing quantum as a binary science breakthrough rather than a capital-allocation game. In the next 1-3 months, the main driver is not technical progress but who can keep funding the burn without repeated dilution; that structurally favors the company with a credible cash runway and real revenue conversion, while the weakest balance sheets stay trapped in narrative trading.

The second-order winner is the infrastructure layer, especially NVDA, because every serious hybrid-quantum architecture needs GPU adjacency regardless of which qubit architecture wins. That creates a classic picks-and-shovels setup: even if quantum adoption slips by 12-24 months, the vendor selling the compute/control stack still monetizes installed demand, while pure plays risk multiple compression as investors start discounting longer commercialization timelines.

Contrarian view: consensus may be overestimating the value of government funding headlines and underestimating how little they matter unless they become repeatable purchase orders. The biggest falsifier for the bearish pure-play stance would be a sequence of backlog-to-revenue conversions over two quarters or a funding event that materially extends runway without dilution; absent that, the sector remains a high-beta financing story, not a fundamentals story.

Key Decisions for Investors

• Long NVDA / short QBTS as the cleanest relative-value expression for 3-6 months: own the monetized platform layer while fading the most funding-dependent pure play; risk/reward is favorable if quantum enthusiasm cools further.
• If using pure plays, prefer IONQ over QBTS on a 6-12 month horizon only as a basket hedge, not an outright conviction long; IONQ’s better revenue traction and balance sheet reduce dilution risk, but the upside still depends on contract conversion.
• Avoid QUBT until there is visible recurring revenue or a funded backlog bridge; this is the weakest quality signal in the group and likely the most vulnerable to multiple compression if risk appetite de-risks again.
• For investors wanting quantum exposure without single-name binary risk, buy NVDA on market-wide AI pullbacks rather than chasing quantum-specific strength; the quantum optionality is free embedded upside, not the thesis.
• Set a watch trigger on any two consecutive quarters of flat-to-up bookings plus narrowing cash burn for IONQ/QBTS; that would invalidate the 'years away' framing and force a reassessment of the entire short thesis.